Therapeutic and diagnostic applications of nanoparticles

Current Drug Targets

Volumn 12, Issue 3, 2011, Pages 357-365

  Youns, Mahmoud ^a   Hoheisel, Jörg D ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer; Microarray; Molecular targets; Nanotechnology

Indexed keywords

ALBUMIN; ALGINIC ACID; CARBON NANOTUBE; CHITOSAN; CISPLATIN; COLLAGEN; COLLOIDAL GOLD; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXTRAN; DOXORUBICIN; FLUOROCARBON; GELATIN; HEPARIN; IMMUNOLIPOSOME; IRON OXIDE; LIPOSOME; MACROGOL; MCC 465; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYCAPROLACTONE; POLYGLUTAMIC ACID; POLYLACTIC ACID; QUANTUM DOT; TAMOXIFEN; TISSUE PLASMINOGEN ACTIVATOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CERAMICS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN MICROARRAY; PROTEOMICS; STOMACH CANCER; STROKE;

EID: 79551623194     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794815257     Document Type: Article

References (119)

1. Tanaka T, Decuzzi P, Cristofanilli M, et al. Nanotechnology for breast cancer therapy. Biomed Microdevices 2009; 11: 49-63.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-71.
3. Haq AI, Zabkiewicz C, Grange P, Arya M. Impact of nanotechnology in breast cancer. Expert Rev Anticancer Ther 2009; 9: 1021-4.
4. Yezhelyev MV, Gao X, Xing Y, et al. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006; 7: 657-67.
5. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82.
6. Bao P, Frutos AG, Greef C, et al. High-sensitivity detection of DNA hybridization on microarrays using resonance light scattering. Anal Chem 2002; 74: 1792-7.
7. Yguerabide J, Yguerabide EE. Resonance light scattering particles as ultrasensitive labels for detection of analytes in a wide range of applications. J Cell Biochem Suppl 2001; Suppl 37: 71-81.
8. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res 2006; 23: 1-30.
9. Liu M, Kono K, Frechet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release 2000; 65: 121-31.
10. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
11. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184-91.
12. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63.
13. Wang X, Wang Y, Chen ZG, Shin DM. Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009; 41: 1-11.
14. Park K, Lee GY, Kim YS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006; 114: 300-6.
15. Park K, Kim K, Kwon IC, et al. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 2004; 20: 11726-31.
16. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst 1999; 16: 245-88.
17. Ulbrich K, Etrych T, Chytil P, et al. Polymeric anticancer drugs with pH-controlled activation. Int J Pharm 2004; 277: 63-72.
18. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-46.
19. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005; 2: 369-81.
20. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005; 46: 795-802.
21. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004; 1663: 167-77.
22. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60.
23. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002; 8: 1172-81.
24. Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000; 60: 6942-9.
25. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002; 62: 7190-4.
26. Eliaz RE, Nir S, Marty C, Szoka FC, Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004; 64: 711-8.
27. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006; 24: 1211-7.
28. Abra RM, Bankert RB, Chen F, et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 2002; 12: 1-3.
29. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004; 95: 608-13.
30. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004; 15: 517-25.
31. Gaur U, Sahoo SK, De TK, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000; 202: 1-10.
32. Laverman P, Carstens MG, Storm G, Moghimi SM. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim Biophys Acta 2001; 1526: 227-9.
33. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable longcirculating polymeric nanospheres. Science 1994; 263: 1600-3.
34. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005; 3: 348-9.
35. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006; 7: 1041-53.
36. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
37. Bissett D, Cassidy J, de Bono JS, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): apolymeric derivative of camptothecin (CPT). Br J Cancer 2004; 91: 50-5.
38. Richards DA, Richards P, Bodkin D, Neubauer MA, Oldham F. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage nonsmall-cell lung cancer: results of a phase II study. Clin Lung Cancer 2005; 7: 215-20.
39. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999; 5: 83-94.
40. Thomson AH, Vasey PA, Murray LS, et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br J Cancer 1999; 81: 99-107.
41. Bilim V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther 2003; 5: 326-30.
42. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer 2005; 12 (Suppl 1): S189-99.
43. Albain KS, Belani CP, Bonomi P, et al. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 2006; 7: 417-9.
44. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006; 24: 39-47.
45. Dipetrillo T, Milas L, Evans D, et al. Paclitaxel poliglumex (PPXXyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol 2006; 29: 376-9.
46. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58: 97-110.
47. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281: 2016-8.
48. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin Chem 2007; 53: 2002-9.
49. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22: 969-76.
50. Sjogren CE, Johansson C, Naevestad A, et al. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging 1997; 15: 55-67.
51. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 2000; 11: 941-6.
52. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484-99.
53. Moore A, Weissleder R, Bogdanov A, Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997; 7: 1140-5.
54. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 1994; 4: 659-68.
55. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007; 81: 53-60.
56. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic Tlymphocyte trafficking to tumors. Cancer Res 2003; 63: 6838-46.
57. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-4.
58. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007; 13: 95-9.
59. Pedroso S, Guillen IA. Microarray and nanotechnology applications of functional nanoparticles. Comb Chem High Throughput Screen 2006; 9: 389-97.
60. Yguerabide J, Yguerabide EE. Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications. Anal Biochem 1998; 262: 137-56.
61. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996; 382: 607-9.
62. Foultier B, Moreno-Hagelsieb L, Flandre D, Remacle J. Comparison of DNA detection methods using nanoparticles and silver enhancement. IEE Proc Nanobiotechnol 2005; 152: 3-12.
63. Boyer D, Tamarat P, Maali A, Lounis B, Orrit M. Photothermal imaging of nanometer-sized metal particles among scatterers. Science 2002; 297: 1160-3.
64. Alexandre I, Hamels S, Dufour S, et al. Colorimetric silver detection of DNA microarrays. Anal Biochem 2001; 295: 1-8.
65. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
66. Youns M, Hoheisel JD, Efferth T. Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumors. Curr Drug Discov Technol 2010; 7: 37-45.
67. Ehdaie B. Application of nanotechnology in cancer research: review of progress in the National Cancer Institute's Alliance for Nanotechnology. Int J Biol Sci 2007; 3: 108-10.
68. Li KC, Pandit SD, Guccione S, Bednarski MD. Molecular imaging applications in nanomedicine. Biomed Microdevices 2004; 6: 113-6.
69. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005; 78: 585-94.
70. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22.
71. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006; 3: 311-24.
72. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006; 103: 6315-20.
73. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 2006; 6: 307-18.
74. Iagaru A, Masamed R, Keesara S, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 2007; 21: 33-8.
75. Kjaer A. Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol l2006; 587: 277-84.
76. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006; 8: 214-22.
77. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 2009; 42: 832-41.
78. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006; 24: 3299-308.
79. Sathe TR, Agrawal A, Nie S. Mesoporous silica beads embedded with semiconductor quantum dots and iron oxide nanocrystals: dual-function microcarriers for optical encoding and magnetic separation. Anal Chem 2006; 78: 5627-32.
80. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122: 598-609.
81. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-46.
82. Fountaine TJ, Wincovitch SM, Geho DH, Garfield SH, Pittaluga S. Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod Pathol 2006; 19: 1181-91.
83. Koo YE, Fan W, Hah H, et al. Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl Opt 2007; 46: 1924-30.
84. Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12: 6677-86.
85. Cho YW, Park SA, Han TH, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 2007; 28: 1236-47.
86. Xing Y, Chaudry Q, Shen C, et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007; 2: 1152-65.
87. Xiao Y, Telford WG, Ball JC, Locascio LE, Barker PE. Semiconductor nanocrystal conjugates, FISH and pH. Nat Methods 2005; 2: 723.
88. Pan D, Lanza GM, Wickline SA, Caruthers SD. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009; 70: 274-85.
89. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008; 83: 761-9.
90. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 2008; 8: 2851-7.
91. Shergill IS, Rao A, Arya M, Patel H, Gill IS. Nanotechnology: potential applications in urology. BJU Int 2006; 97: 219-20.
92. Tsiouris A, Ahmed HU, Kaisary AV. Nanotechnology: potential applications in urology. BJU Int 2006; 98: 231-2.
93. Gommersall L, Shergill IS, Ahmed HU, et al. Nanotechnology and its relevance to the urologist. Eur Urol 2007; 52: 368-75.
94. Shulga OV, Zhou D, Demchenko AV, Stine KJ. Detection of free prostate specific antigen (fPSA) on a nanoporous gold platform. Analyst 2008; 133: 319-22.
95. Briman M, Artukovic E, Zhang L, et al. Direct electronic detection of prostate-specific antigen in serum. Small 2007; 3: 758-62.
96. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9.
97. Baron R, Zayats M, Willner I. Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: assays for the detection of neurotransmitters and of tyrosinase activity. Anal Chem 2005; 77: 1566-71.
98. Haes AJ, Chang L, Klein WL, Van Duyne RP. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 2005; 127: 2264-71.
99. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2005; 102: 2273-6.
100. Partlow KC, Chen J, Brant JA, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007; 21: 1647-54.
101. Youns M, Efferth T, Reichling J, et al. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol 2009; 78: 273-83.
102. Youns M, Efferth T, Hoheisel JD. Microarray analysis of gene expression in medicinal plant research. Drug Discov Ther 2009; 3: 200-207.
103. Taton TA, Mirkin CA, Letsinger RL. Scanometric DNA array detection with nanoparticle probes. Science 2000; 289: 1757-60.
104. Francois P, Bento M, Vaudaux P, Schrenzel J. Comparison of fluorescence and resonance light scattering for highly sensitive microarray detection of bacterial pathogens. J Microbiol Methods 2003; 55: 755-62.
105. Ji M, Hou P, Li S, He N, Lu Z. Colorimetric silver detection of methylation using DNA microarray coupled with linker-PCR. Clin Chim Acta 2004; 342: 145-53.
106. Huber M, Wei TF, Muller UR, et al. Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. Nucleic Acids Res 2004; 32: e137.
107. Danscher G, Norgaard JO, Baatrup E. Autometallography: tissue metals demonstrated by a silver enhancement kit. Histochemistry 1987; 86: 465-9.
108. Storhoff JJ, Marla SS, Bao P, et al. Gold nanoparticle-based detection of genomic DNA targets on microarrays using a novel optical detection system. Biosens Bioelectron 2004; 19: 875-83.
109. Bao YP, Huber M, Wei TF, et al. SNP identification in unamplified human genomic DNA with gold nanoparticle probes. Nucleic Acids Res 2005; 33: e15.
110. Gerion D, Chen F, Kannan B, et al. Room-temperature singlenucleotide polymorphism and multiallele DNA detection using fluorescent nanocrystals and microarrays. Anal Chem 2003; 75: 4766-72.
111. Bruchez M, Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 1998; 281: 2013-6.
112. Bruchez MP. Turning all the lights on: quantum dots in cellular assays. Curr Opin Chem Biol 2005; 9: 533-7.
113. Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev Proteomics 2009; 6: 115-8.
114. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
115. Deutsch EW, Eng JK, Zhang H, et al. Human Plasma PeptideAtlas. Proteomics 2005; 5: 3497-500.
116. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905.
117. Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003; 19: 1-10.
118. Geho DH, Lahar N, Ferrari M, Petricoin EF, Liotta LA. Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed Microdevices 2004; 6: 231-9.
119. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 2003; 301: 1884-6.